key: cord-0895036-4ufn7wt1
authors: Meenakumari, Ramaswamy; Thangaraj, Karuppiah; Sundaram, Arunachalam; Sundaram, Malayappan Meenakshi; Shanmugapriya, Ponnappan; Mariappan, Andi; George, Melvin; Suba, Venkatesan; Rajalakshmi, Elumalai; Sendhilkumar, Muthappan
title: Clinical outcomes among COVID-19 patients managed with modern and traditional Siddha medicine -A retrospective cohort study, Chennai, Tamil Nadu, India, 2020
date: 2021-06-25
journal: J Ayurveda Integr Med
DOI: 10.1016/j.jaim.2021.06.010
sha: 9f20893ede932d0861ea1df972680f575de059cf
doc_id: 895036
cord_uid: 4ufn7wt1

BACKGROUND: Kabasura Kudineer (KSK) is a Siddha polyherbal decoction recommended by the Ministry of AYUSH and the Tamil Nadu government to prevent and manage COVID-19 in India. In this context, we aimed to determine the outcome of integrated therapy for COVID-19 using KSK in virologic clearance and length of hospital stay. METHODS: It was a single-centre, retrospective cohort study. We included the COVID-19 patients admitted to SRM Medical College Hospital and Research Centre, Chennai, during May-June 2020.The KSK was administered along with the standard of care for all the patients. We collected demographic, clinical data and laboratory parameters data and were presented as frequencies and proportions. RESULTS: We collected 204 COVID-19 positive patients’ data. The mean (SD) age was 39.5 (13.4) years with a range of 13-79. Majority of the patients were male (n=157; 77%), 28% (n=58) had any co-morbidities and 61% (n=131) were with mild symptoms. Fever (n=57;27.9%) and cough (n=53; 25.9%) were the commonly reported symptoms. Paracetamol (n=135; 66.7%) and Zincovit (n=197, 96.6%) were the commonly administered medicines along with KSK. About 74% of asymptomatic (n=54) and 65% of mild symptomatic (n=85) patients turned negative for COVID-19 in RT-PCR within 4-7 days. There was a significant difference in the blood parameters (p<0.05) after the integrated treatment. CONCLUSION: The use of KSK with standard care of treatment in COVID-19 treatment had notable results in the duration taken for virologic clearance, thereby reducing the length of hospital stay and improvement in laboratory parameters.

The National Institute of Siddha (NIS) which is located in Chennai, Tamil Nadu with its 1 excellence in research and higher education in Siddha system of medicine and played a pivotal 2 role in COVID-19 response. NIS has involved in COVID-19 response activities in collaboration 3 with medical, academic and research institutions in Tamil Nadu [12] . The SRM Medical college 4 Hospital and Research Centre, a tertiary care centre in Tamil Nadu, is one such health facility in 5 which the KSK was administered along with standard care of treatment for COVID-19 patients 6 under the supervision of Siddha faculty of NIS as a collaborative activity. This polyherbal 7 decoction is used in general practice in Siddha system. Though it is yet to be demonstrated by 8 controlled clinical trials for its safety and efficacy, we got the opportunity to document the 9 experience of administering KSK along with the routine care at SRM health facility. During the 10 pandemic, KSK has been advocated to administer as a preventive measure and the standard care 11 for asymptomatic, mild and moderate symptomatic COVID-19 patients based on the evidence 12 showing anti-viral properties in the preliminary pharmacological and phytochemical studies [11] . 13 However, clinical documentation is highly needed to know the benefit of integrated treatment. In 14 this context, we aimed to determine the clinical outcome of integrated therapy for COVID-19 15 using Kabasura kudineer in terms of virologic clearance for COVID-19 in RT-PCR and to 16 estimate the length of hospital stay. 17 20 The study site is SRM Medical College Hospital and Research Centre, Chennai, Tamil Nadu. 21 This is a tertiary care hospital which serves around 3, 00,000 populations in the surrounding 22 areas. 23 24 COVID-19 positive patients who were admitted in SRM Medical College Hospital and treated 25 with integrated therapy. 26 27 All patients included in this study were diagnosed for COVID-19 based on the World Health 28 Organization (WHO) guidelines those who had influenza like illness and were SARS-CoV-2 consecutive COVID-19 positive patients with asymptomatic and mild symptoms irrespective of 1 age and gender who were admitted during the study period and treated with KSK along with the 2 standard care of treatment. 5 This was a single-centre retrospective cohort study. 6 7 2.5. Study period: 8 The COVID-19 patients admitted during May -June 2020 were included in this study. 17 The time duration is taken from hospital admission to the discharge for a patient. 20 All the COVID-19 patients were managed symptomatically with the administration of 21 antipyretics, antibiotics, expectorant, Zinc and Vitamin C and the regular treatment related to 22 their comorbid conditions such as anti-diabetic and anti-hypertensive drugs. 25 The KSK is a polyherbal formulation comprising of 15 medicinal herbs ( Table 1 ). The medicine 26 was purchased from a Good Manufacturing Practice (GMP) certified company in order to ensure 27 the good quality. The decoction was prepared by adding 10 gms of KSK powder with 240 ml of 28 water, boiled and reduced to one-fourth (60 ml) and filtered. The decoction (60 ml) was 29 administered orally thrice daily, 20 min before food for all the patients. Each dose of KSK 30 decoction was administered to all the patients within 3 hours of preparation. The pharmacist of 31 J o u r n a l P r e -p r o o f 6 | P a g e NIS has prepared the decoction to ensure the quality of medicine. The clinical and paramedical 1 SRM hospital staff ascertained that the medicine was administered to the patients as per the 2 treatment protocol prescribed. First dose of KSK was administered within 24 hrs of admission 3 and continued thrice daily throughout the hospital stay. The patients were stayed in the hospital 4 until they get the virologic clearance by RT-PCR test. Further, they were advised to continue 5 KSK twice daily for at-least a week after discharge. 6 7 2.9. Data collection methods 8 We used data abstraction forms to retrieve information from the medical records. The 9 information collected are the demographic details such as age gender, hospitalization details such 10 as date of admission and discharge, medical history for comorbid conditions, vital parameters, all 11 clinical signs and symptoms including other than for COVID-19. The laboratory parameters of 12 blood test, RT-PCR findings (initial date of positive and the date when the patient became 13 negative for COVID-19 in RT-PCR) and the medical interventions underwent such as KSK 14 administration and the list of drugs administered under standard treatment of care also collected. 15 We included all the patients admitted and treated in the study period, irrespective of the date of 16 laboratory confirmation and the date of admission to the hospital. Hence, there may be a time lag 17 between the date of first RT PCR test on which they found positive and the date of admission in 18 the hospital for some patients. The decoction of KSK was administered three times in a day to all 19 the asymptomatic and patients with mild symptoms. The KSK was administered irrespective of 26 The collected data were entered in excel and cleaned before analysis. Continuous variables were 27 described as means and SD, or as median and range and the categorical variables were expressed 28 as frequency and proportions. Paired t-test was done to find out the significant difference in any 29 paired variables. All statistical analyses were performed using SPSS version 16.0. 2020, the length of hospital stay in standard allopathy care of mild cases was 10 days ( [16] . In 4 the current observation, around two-thirds of the mild symptomatic patients were relieved from 5 symptoms, became negative for RT-PCR test, and discharged from the hospital in 10 days, 6 which is as mentioned in the discharge policy issued by the MoHFW. The course of integrated 7 treatment with KSK ranged from 4-18 days irrespective of the symptom status, which is shorter 8 than the studies reported earlier from China (4-53 days) and from other countries (4-21 days) 9 outside China ( [17] . 10 The integrated treatment shortens the time taken to become negative for COVID-19 and thereby 11 reducing the length of hospital stay. With these observations, it may be postulated that if KSK is 12 administered with the routine treatment, it will benefit the effective management of COVID-19. 13 People with known diabetes and hypertension and older age group are at a greater risk of 14 contracting infection, worse prognosis and mortality with respect to COVID-19 infection 15 [18, 19] . In contrary the time taken for virologic clearance was 5-15 days for both the group who 16 had either diabetes or hypertension in the current observation. 17 18 Lymphopenia is reported in severe cases and the patients with poor prognosis [20, 21] . During the 19 current integrated therapy with KSK the identified patients with low count of lymphocytes, 20 eosinophils and basophils at the time of admission have shown significant improvement at 21 discharge. It is notable to mention that many of the phytoconstituents of KSK formulation are 22 studied for their immunomodulatory potential and activities [22, 23] . The ingredients in the 23 selected Siddha formulation KSK has anti-pyretic, anti-inflammatory and immunomodulatory 24 activities, which can appropriately suitable for the management of COVID-19 [11, [22] [23] [24] [25] [26] [27] [28] [29] [30] . 25 Research studies are conducted to analyse phytochemicals from KSK against the SARS-CoV-2 26 through structure-based in silico molecular docking and identified potent anti-COVID-19 natural 27 compounds [31, 32] . Furthermore, clinical trials are also implemented to determine the efficacy 28 of KSK in comparison with other standard treatment protocol [33] .

This study has few limitations: (i) No randomization involved, thereby leading to selection bias. 13 We recommend conducting studies with a comparator group to determine the significant 14 difference in the outcome and randomized controlled trials to evaluate the safety and efficacy of 15 KSK. 16 17 The authors declare that there is no competing interest. 18 

World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard

What we know about Long-term effects of COVID-19

Integrative medicine considerations for convalescence from mild-to-moderate COVID-19 disease

Integrative medicine for COVID-19: researches and evidence

Government of Tamil Nadu. Directorate of Public Health & Preventive Medicine

Health & Family Welfare Department

Yugimunivar vaidhyachinthamani (Perunool 800, Tamil)

Palani Thandayuthapani Devasthanam publications, Directorate of Indian systems of Medicine

Chennai: The Directorate of Indian Medicine and Homoeopathy

Siddha Vaidhya Thirattu Chennai: The Directorate of Indian Medicine and Homoeopathy

National Institute of Siddha

Clinical management of severe acute respiratory infection when novel coronavirus ( 2019-nCoV) infection is suspected: interim guidance

Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV)

World Health Organization declares global emergency: A review of the 2019 novel corona virus (COVID-19). International journal of surgery

Ministry of Health and Family welfare. Revised Discharge Policy for COVID-19

COVID-19 length of hospital stay: a systematic review and data synthesis

Association between COVID-19 prognosis and disease presentation, comorbidities and chronic treatment of hospitalized patients. PloS one

Older people are at highest risk from COVID-19, but all must act to prevent community spread. World Health Organization for Europe

Lymphopenia in COVID 19: Therapeutic opportunities

Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis

Tinosporacordifolia with reference to biological and microbial properties

Andrographis paniculata (Burm. f.) Wall. ex J o u r n a l P r e

Nees: a review of ethnobotany, phytochemistry, and pharmacology

Antiviral screening of forty-two Egyptian medicinal plants

Costus speciosus: an important medicinal plant. International journal of science and Research

In vivo study of the anti-inflammatory and antitumor activities of leaves from Plectranthus amboinicus (Lour.) Spreng (Lamiaceae)

Syzygium aromaticum L.(Myrtaceae): Traditional uses, bioactive chemical constituents, pharmacological and toxicological activities

Antiinflammatory, antinociceptive, and antioxidant activities of methanol and aqueous extracts of Anacyclus pyrethrum roots. Frontiers in pharmacology

Anti-HSV-2 activity of Terminalia chebula Retz extract and its constituents, chebulagic and chebulinic acids. BMC Complement Altern Med

Cissampelos pareira Linn: Natural source of potent antiviral activity against all four dengue virus serotypes. PLoS neglected tropical diseases

Molecular Docking Studies on the Anti-viral Effects of Compounds From Kabasura Kudineer on SARS-CoV-2 3CLpro. Frontiers in molecular biosciences

In silico computational screening of Kabasura Kudineer-official Siddha formulation and JACOM against SARS-CoV-2 spike protein. Journal of Ayurveda and integrative medicine

The efficacy of Siddha Medicine, Kabasura Kudineer (KSK) compared to Vitamin C & Zinc (CZ) supplementation in the management of asymptomatic COVID-19 cases: A structured summary of a study protocol for a randomised controlled trial